Qurient Quarterly Report: Pipeline Progress and Financial Stability
Telacebec (Q203) showed 100% cure rate in Buruli ulcer Phase 2a in Australia; US FDA Priority Review Voucher (PRV) virtually assured (current trading ~$200M)
Mocaciclib (Q901) completed dose escalation in Phase 1 with high safety (no toxicity up to 90mg/m2); combo with MSD/Keytruda and NCI collaboration for SCLC ongoing
QP101 dual-payload ADC shows superior efficacy in T-DXd resistant models in preclinical; Synaffix license deal ($249.5M total)
Adrixetinib (Q702): cGvHD Phase 1b IND approved in Spain; AML trial with MD Anderson; exploring biomarkers for Keytruda combo